Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VKTX Stock Forecast 2025-2026
$24.99
Current Price
$2.88B
Market Cap
Buy 16
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to VKTX Price Targets
+400.2%
To High Target of $125.00
+290.2%
To Median Target of $97.50
+20.0%
To Low Target of $30.00
VKTX Price Momentum
+5.4%
1 Week Change
-2.6%
1 Month Change
-66.4%
1 Year Change
-37.9%
Year-to-Date Change
-69.5%
From 52W High of $81.86
+32.1%
From 52W Low of $18.92
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Viking Therapeutics (VKTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VKTX and similar high-potential opportunities.
Latest VKTX Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, VKTX has a bullish consensus with a median price target of $97.50 (ranging from $30.00 to $125.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $24.99, the median forecast implies a 290.2% upside. This outlook is supported by 16 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Steven Seedhouse at Raymond James, projecting a 400.2% upside. Conversely, the most conservative target is provided by Richard Law at Goldman Sachs, suggesting a 20.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VKTX Analyst Ratings
16
Buy
2
Hold
0
Sell
VKTX Price Target Range
Low
$30.00
Average
$97.50
High
$125.00
Current: $24.99
Latest VKTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VKTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 24, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Apr 24, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $102.00 |
| Apr 17, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Apr 8, 2025 | Goldman Sachs | Richard Law | Neutral | Initiates | $30.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Feb 13, 2025 | Scotiabank | George Farmer | Sector Outperform | Initiates | $102.00 |
| Feb 7, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $96.00 |
| Feb 7, 2025 | Maxim Group | Naz Rahman | Buy | Maintains | $70.00 |
| Feb 7, 2025 | Citigroup | David Lebowitz | Neutral | Initiates | $38.00 |
| Feb 6, 2025 | Piper Sandler | Biren Amin | Overweight | Maintains | $71.00 |
| Feb 6, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Feb 6, 2025 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $125.00 |
| Jan 17, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $102.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Dec 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Dec 2, 2024 | Piper Sandler | Biren Amin | Overweight | Initiates | $74.00 |
| Nov 27, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
Viking Therapeutics Inc. (VKTX) Competitors
The following stocks are similar to Viking Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VKTX
Viking Therapeutics
mkt cap
2.88B
Viking Therapeutics Inc. (VKTX) Financial Data
Viking Therapeutics Inc. has a market capitalization of $2.88B with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -14.4%.
Valuation Metrics
Market Cap
$2.88B
Enterprise Value
$1.96B
P/E Ratio
0.0x
PEG Ratio
-16.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+30.4%
Current Ratio
44.2x
Debt/Equity
0.1x
ROE
-14.4%
ROA
-11.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Viking Therapeutics Inc. (VKTX) Business Model
About Viking Therapeutics Inc.
What They Do
Develops therapeutics for metabolic and endocrine disorders.
Business Model
Viking Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and advancement of small molecule drug candidates for metabolic and endocrine disorders. The company generates revenue through the development of innovative therapeutics aimed at unmet medical needs, particularly in lipid metabolism and musculoskeletal health, addressing significant health challenges like non-alcoholic steatohepatitis (NASH).
Additional Information
Headquartered in San Diego, California, Viking Therapeutics plays a vital role in the biotechnology sector, targeting diseases related to fat metabolism. The company aims to create transformative therapies in response to the healthcare demands of an aging population and rising chronic health issues, potentially influencing healthcare outcomes and drug development trends.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
45
CEO
Dr. Brian Lian Ph.D.
Country
United States
IPO Year
2015
Website
www.vikingtherapeutics.comViking Therapeutics Inc. (VKTX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Apr 24, 2025
By Ahan Chakraborty
Analyst Blog
Latest News
Quick Summary
Viking Therapeutics Inc. (NASDAQ: VKTX) reported earnings on April 23, leading to a rise in stock price despite no new information being provided in the report.
Why It Matters
Viking Therapeutics' stock rise despite no new information suggests investor optimism or speculative trading, indicating potential volatility and sentiment-driven movements in the stock.
Source: MarketBeat
Market Sentiment:
Negative
Quick Summary
Viking Therapeutics, Inc. will host its Q1 2025 financial results conference call on April 23, 2025, at 4:30 PM ET with key executives and financial analysts participating.
Why It Matters
The conference call highlights Viking Therapeutics' Q1 2025 results, providing insights into financial performance and strategic direction, crucial for assessing investment potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Viking Therapeutics' VK2735 is showing promise in weight loss and safety, with Phase 3 and Phase 2 trials upcoming. The company has no revenue but strong cash reserves and rising R&D spending.
Why It Matters
Viking Therapeutics' VK2735 shows promise in weight loss treatments, but competition from major players may impact market share. High R&D costs and upcoming trials could affect financial stability.
Source: Seeking Alpha
Market Sentiment:
Neutral
Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
4 days ago
Quick Summary
Viking Therapeutics will host a conference call today at 4:30 p.m. ET. They expect Phase 3 trials for VK2735 to start in Q2 2025 and reported a cash position of $852M.
Why It Matters
The scheduled conference call and updates on clinical trials, cash position, and manufacturing agreements signal potential growth and value for Viking Therapeutics, impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VKTX's Q1 earnings fell short of estimates, but the company plans to begin late-stage development of its obesity injection by the end of June.
Why It Matters
VKTX's earnings miss may signal operational challenges, affecting investor confidence. However, advancing its obesity injection could drive future growth and market interest.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Viking Therapeutics (NASDAQ: VKTX) will hold its Q1 earnings call on the 23rd, focusing on updates for VK2735, VK2809, and VK0214 clinical candidates.
Why It Matters
Viking Therapeutics' upcoming earnings call is crucial for assessing the potential of its key drug candidates, which could significantly impact stock performance and market sentiment.
Source: See It Market
Market Sentiment:
Neutral
Frequently Asked Questions About VKTX Stock
What is Viking Therapeutics Inc.'s (VKTX) stock forecast for 2025?
Based on our analysis of 23 Wall Street analysts, Viking Therapeutics Inc. (VKTX) has a median price target of $97.50. The highest price target is $125.00 and the lowest is $30.00.
Is VKTX stock a good investment in 2025?
According to current analyst ratings, VKTX has 16 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VKTX stock?
Wall Street analysts predict VKTX stock could reach $97.50 in the next 12 months. This represents a 290.2% increase from the current price of $24.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Viking Therapeutics Inc.'s business model?
Viking Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and advancement of small molecule drug candidates for metabolic and endocrine disorders. The company generates revenue through the development of innovative therapeutics aimed at unmet medical needs, particularly in lipid metabolism and musculoskeletal health, addressing significant health challenges like non-alcoholic steatohepatitis (NASH).
What is the highest forecasted price for VKTX Viking Therapeutics Inc.?
The highest price target for VKTX is $125.00 from Steven Seedhouse at Raymond James, which represents a 400.2% increase from the current price of $24.99.
What is the lowest forecasted price for VKTX Viking Therapeutics Inc.?
The lowest price target for VKTX is $30.00 from Richard Law at Goldman Sachs, which represents a 20.0% increase from the current price of $24.99.
What is the overall VKTX consensus from analysts for Viking Therapeutics Inc.?
The overall analyst consensus for VKTX is bullish. Out of 23 Wall Street analysts, 16 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $97.50.
How accurate are VKTX stock price projections?
Stock price projections, including those for Viking Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 8:04 AM UTC